Kuvan in People With Schizophrenia and Schizoaffective Disorder
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Rater blinded trial of six weeks of Kuvan vs. multivitamin in 60 outpatients with
schizophrenia or schizoaffective disorder. The aims are to evaluate an anticipated clinical
response to Kuvan treatment including negative symptom and cognitive deficits, evaluate
safety of Kuvan treatment for schizophrenic patients and evaluate the relationship of changes
in plasma Kuvan levels and efficacy outcomes.